SG Americas Securities LLC lowered its stake in shares of Orthofix International N.V. (NASDAQ:OFIX) by 69.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,094 shares of the medical device company’s stock after selling 9,283 shares during the quarter. SG Americas Securities LLC’s holdings in Orthofix International N.V. were worth $190,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in OFIX. Teachers Advisors LLC increased its position in Orthofix International N.V. by 18.2% during the fourth quarter. Teachers Advisors LLC now owns 35,600 shares of the medical device company’s stock worth $1,288,000 after acquiring an additional 5,489 shares during the period. Capstone Asset Management Co. bought a new position in Orthofix International N.V. during the first quarter worth $204,000. Louisiana State Employees Retirement System bought a new position in Orthofix International N.V. during the first quarter worth $278,000. Nationwide Fund Advisors increased its position in Orthofix International N.V. by 94.7% during the first quarter. Nationwide Fund Advisors now owns 24,441 shares of the medical device company’s stock worth $932,000 after acquiring an additional 11,888 shares during the period. Finally, American Century Companies Inc. increased its position in Orthofix International N.V. by 68.9% during the first quarter. American Century Companies Inc. now owns 175,522 shares of the medical device company’s stock worth $6,696,000 after acquiring an additional 71,599 shares during the period. 94.40% of the stock is currently owned by institutional investors and hedge funds.
In other Orthofix International N.V. news, insider Raymond Fujikawa sold 6,364 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $47.06, for a total transaction of $299,489.84. Following the transaction, the insider now owns 31,084 shares in the company, valued at approximately $1,462,813.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brad Mason sold 2,733 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $48.10, for a total value of $131,457.30. Following the transaction, the chief executive officer now owns 188,053 shares in the company, valued at approximately $9,045,349.30. The disclosure for this sale can be found here. Insiders have sold a total of 23,406 shares of company stock worth $1,138,531 in the last quarter. Company insiders own 5.60% of the company’s stock.
Shares of Orthofix International N.V. (OFIX) opened at 47.73 on Thursday. The company has a market cap of $867.25 million, a price-to-earnings ratio of 111.78 and a beta of 0.22. Orthofix International N.V. has a one year low of $32.51 and a one year high of $50.40. The firm has a 50-day moving average of $47.80 and a 200 day moving average of $43.18.
Orthofix International N.V. (NASDAQ:OFIX) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.01. The firm had revenue of $108.90 million for the quarter, compared to analysts’ expectations of $102.94 million. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.41 EPS. Equities research analysts anticipate that Orthofix International N.V. will post $1.56 EPS for the current year.
A number of equities analysts recently issued reports on OFIX shares. Langenberg & Company reaffirmed a “buy” rating and set a $53.25 target price on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. Zacks Investment Research raised shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. BTIG Research started coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 21st. They set a “buy” rating and a $52.00 target price on the stock. Ladenburg Thalmann Financial Services started coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. They set a “buy” rating and a $53.25 target price on the stock. Finally, TheStreet raised shares of Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th. Seven research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $52.75.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.